Zai Lab Announces Participation in March Investor Conferences
SHANGHAI and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in March 2023:
Jefferies 2023 Biotech on the Bay SummitPanel Discussion: Thursday, March 16, 2023, 12:15 p.m. ETLocation: Miami
26th Credit Suisse Asian Investment ConferenceDate: Monday, March 20 to Thursday, March 23, 2023Location: Hong Kong
About Zai Lab
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.
For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
For more information, please contact:
Investor Relations: Lina Zhang+86 136 8257 6943[email protected]
Media: Christine Drury / Xiaoyu Chen+1 (317) 385-9227 / +86 185 0015 5011[email protected] / [email protected]
Source: Zai Lab Limited
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Building Global Trust in the AI Search Era: DigiMentumPR Explores the Future of PR for Technology Brands
- RWA INC and Sproutly Expand Collaboration to Bring Real-World Environmental Assets On-Chain
- MEDIA ADVISORY: "The Mosquers" Muslim Film Festival Returns to Edmonton Sept 17-20, 2026 with Mahershala Ali’s Your Mother Your Mother Your Mother
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Credit Suisse, Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share